K-924 Phase III Confirmatory Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.

Also called NCT04289649

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 293 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04289649
Other papers using this trial's data
  • Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial Journal of atherosclerosis and thrombosis, 2023-11-01 DOI, PubMed 36908150, PMC10627746 In the PMC Open Access subset under CC BY-NC-SA.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04289649. Randomized; triple masking; primary purpose treatment. Start 2020-04-02 (actual); primary completion 2020-11-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
K-924 Phase III Confirmatory Study
Condition
Hypercholesterolemia
Intervention (Drug)
K-924 LD
Intervention (Drug)
K-924 HD
Intervention (Drug)
K-924 LD Placebo
Intervention (Drug)
K-924 HD Placebo
Lead sponsor
Kowa Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04289649
Content hash
71247c3162b3e31488dc226607fd5cc1a1456208c0d80c9079df2280c30b16bf